Search

Arrowhead Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

65.7 -0.54

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

65.33

Maximum

67.22

Fő mutatók

By Trading Economics

Bevétel

-51M

-184M

Értékesítés

1.5M

75M

P/E

Szektor átlag

47.744

55.725

Egy részvényre jutó nyereség

-1.36

Profit margin

-244.188

Munkavállalók

711

EBITDA

-47M

-154M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+62.95% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 24.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-2.4B

9.7B

Előző nyitás

66.24

Előző zárás

65.7

Hangulat hírek alapján

By Acuity

68%

32%

276 / 339 Rangsor szerint Healthcare

Arrowhead Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 24. 19:46 UTC

News

Arrowhead Pharmaceuticals shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a price target of $74 amid mixed fiscal results.

2026. szept. 23. 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026. szept. 22. 20:06 UTC

Arrowhead Pharmaceuticals Inc is higher in Tuesday's trading, having gained notably from Monday's close, despite pulling back from a mid-afternoon peak.

2026. szept. 21. 23:25 UTC

Arrowhead Pharmaceuticals Inc declined in after-market trading, moving lower from Monday's close and remaining near the lower end of its one-month trading range.

2026. szept. 18. 23:12 UTC

Social Media

Arrowhead Pharmaceuticals Inc is experiencing notable strength in after-market trading, rising sharply despite initial sales figures for TRYNGOLZA being deemed unreliable by Ionis' CEO.

2026. szept. 17. 22:56 UTC

Arrowhead Pharmaceuticals Inc is trading roughly flat in after-market hours, maintaining little change since Thursday's close amid a notable decline over the past month.

2026. szept. 16. 22:31 UTC

Social Media

Arrowhead Pharmaceuticals Inc is rising in after-market trading, rebounding sharply amid retail commentary on its resilience despite challenges in the biotechnology sector.

2026. szept. 15. 23:01 UTC

Event

Arrowhead Pharmaceuticals is gaining in after-market hours following positive interim data from its ARO-DIMER-PA trial, amid a broader market uptrend.

2026. szept. 14. 19:16 UTC

Social Media

Arrowhead Pharmaceuticals Inc shares are lower amid broader market pressures, driven by renewed inflation concerns and supply chain disruptions.

2026. szept. 11. 23:26 UTC

Arrowhead Pharmaceuticals shares rose in after-market trading, amid steady U.S. inflation data and speculation about potential Federal Reserve interest rate hikes.

2026. szept. 10. 19:56 UTC

Arrowhead Pharmaceuticals shares are higher during Thursday's session, despite fluctuations and remaining below the 20-day moving average amid broader market trends.

2026. szept. 9. 19:36 UTC

Social Media

Arrowhead Pharmaceuticals is lower today despite Citi initiating coverage with a "Buy" rating and a price target of $108. The stock has declined for four sessions.

2026. szept. 8. 19:36 UTC

Social Media

Arrowhead Pharmaceuticals Inc is trading lower today, following Citi's initiation of coverage with a Buy rating and a $108 price target.

2026. szept. 4. 23:10 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours following Friday's close. Broader market caution amid mixed economic signals may be influencing this movement.

2026. szept. 3. 19:46 UTC

News

Arrowhead Pharmaceuticals shares are higher as the company announces participation in several upcoming investor conferences, enhancing visibility among investors and analysts.

2026. szept. 2. 23:01 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, reflecting a notable decline since Wednesday's close amid broader market tensions and rising oil prices.

2026. szept. 1. 19:46 UTC

Social Media
News

HC Wainwright reiterated its Buy rating on Arrowhead Pharmaceuticals, maintaining a $120 price target as shares advance during the session.

2026. aug. 31. 20:01 UTC

Event
News
Social Media

Arrowhead Pharmaceuticals shares are lower despite promising Phase 3 results for plozasiran, which showed significant triglyceride reductions in patients.

2026. aug. 28. 21:01 UTC

Arrowhead Pharmaceuticals Inc. shares are higher in after-market trading, continuing a modest rise since Friday's close, despite remaining below the 20-day moving average.

2026. aug. 26. 19:56 UTC

Arrowhead Pharmaceuticals shares are lower today, trading within a narrow range without any specific news or developments identified.

2026. aug. 25. 23:31 UTC

Arrowhead Pharmaceuticals shares moved higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

2026. aug. 21. 19:46 UTC

News

Arrowhead Pharmaceuticals shares are lower as Director Michael Perry sold 11,600 shares, reducing his ownership. Rising Treasury yields may also affect sentiment in biotechnology.

2026. aug. 20. 21:26 UTC

Arrowhead Pharmaceuticals Inc shares are lower during after-market hours. Broader market pressure from rising U.S. Treasury yields may be influencing sentiment.

2026. aug. 19. 19:26 UTC

Correlated Moves

Arrowhead Pharmaceuticals shares are higher Wednesday, supported by gains in the biotech sector, as the stock remains above its 20-day moving average.

2026. aug. 18. 23:01 UTC

Arrowhead Pharmaceuticals shares are lower in after-market hours, continuing a decline since Tuesday's close amid broader market concerns over rising U.S. Treasury yields.

2026. aug. 14. 19:26 UTC

Arrowhead Pharmaceuticals Inc shares are higher during Friday's session, trading above their 20-day moving average and near the top of their one-month range.

2026. aug. 13. 20:06 UTC

Correlated Moves

Arrowhead Pharmaceuticals Inc is declining today amid broader sector pressures, reflecting challenges in the biotech sector linked to the performance of LABU.

2026. aug. 12. 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

2026. aug. 11. 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

2026. aug. 6. 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.

Társak összehasonlítása

Árváltozás

Arrowhead Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

62.95% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 109.111 USD  62.95%

Magas 126 USD

Alacsony 74 USD

12 Wall Street elemző 12 hónapos célárain alapulva a(z)Arrowhead Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

12 ratings

11

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

276 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.